Earnings summaries and quarterly performance for Zura Bio.
Executive leadership at Zura Bio.
Board of directors at Zura Bio.
AM
Amit Munshi
Detailed
Chairman of the Board
AP
Arnout Ploos van Amstel
Detailed
Director
DB
Dan Becker
Detailed
Director
JJ
Jennifer Jarrett
Detailed
Director
NG
Neil Graham
Detailed
Director
RL
Robert Lisicki
Detailed
Director
SK
Sandeep Kulkarni
Detailed
Director
SS
Someit Sidhu
Detailed
Director
SS
Steve Schoch
Detailed
Director
Research analysts covering Zura Bio.
Recent press releases and 8-K filings for ZURA.
Zura Bio Reports Q3 2025 Financial Results and Clinical Trial Progress
ZURA
Earnings
Guidance Update
New Projects/Investments
- Zura Bio reported $139.0 million in cash and cash equivalents as of September 30, 2025, which is expected to fund planned operations through 2027.
- The company recorded a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025.
- Research and development expenses for Q3 2025 were $11.9 million, reflecting the continued advancement of the tibulizumab Phase 2 clinical trials.
- Zura Bio continued to advance its two Phase 2 clinical trials for tibulizumab (TibuSHIELD for hidradenitis suppurativa and TibuSURE for systemic sclerosis), with topline data for both studies expected in the second half of 2026.
Nov 13, 2025, 11:30 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more